These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23878286)

  • 1. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Chung WJ; Kim HS; Kim N; Choi CG; Kim SJ
    Radiology; 2013 Nov; 269(2):561-8. PubMed ID: 23878286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
    Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
    Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
    AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
    Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Barajas RF; Chang JS; Segal MR; Parsa AT; McDermott MW; Berger MS; Cha S
    Radiology; 2009 Nov; 253(2):486-96. PubMed ID: 19789240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers.
    Bhooshan N; Giger ML; Jansen SA; Li H; Lan L; Newstead GM
    Radiology; 2010 Mar; 254(3):680-90. PubMed ID: 20123903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Local Tumor Recurrence After Definitive Treatment of Head and Neck Squamous Cell Carcinoma: Histogram Analysis of Dynamic Contrast-Enhanced T1-Weighted Perfusion MRI.
    Choi SH; Lee JH; Choi YJ; Park JE; Sung YS; Kim N; Baek JH
    AJR Am J Roentgenol; 2017 Jan; 208(1):42-47. PubMed ID: 27680294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?
    Donati OF; Jung SI; Vargas HA; Gultekin DH; Zheng J; Moskowitz CS; Hricak H; Zelefsky MJ; Akin O
    Radiology; 2013 Aug; 268(2):440-50. PubMed ID: 23481164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma: Application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading.
    Jung SC; Yeom JA; Kim JH; Ryoo I; Kim SC; Shin H; Lee AL; Yun TJ; Park CK; Sohn CH; Park SH; Choi SH
    AJNR Am J Neuroradiol; 2014 Jun; 35(6):1103-10. PubMed ID: 24384119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.
    Dong Y; Liu Q
    J Comput Assist Tomogr; 2012; 36(4):361-6. PubMed ID: 22805661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
    Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.
    Huang W; Tudorica LA; Li X; Thakur SB; Chen Y; Morris EA; Tagge IJ; Korenblit ME; Rooney WD; Koutcher JA; Springer CS
    Radiology; 2011 Nov; 261(2):394-403. PubMed ID: 21828189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is the best advanced MR imaging protocol for predicting recurrent metastatic brain tumor following gamma-knife radiosurgery: focused on perfusion method.
    Koh MJ; Kim HS; Choi CG; Kim SJ
    Neuroradiology; 2015 Apr; 57(4):367-76. PubMed ID: 25592446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
    Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
    Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.
    Narang J; Jain R; Arbab AS; Mikkelsen T; Scarpace L; Rosenblum ML; Hearshen D; Babajani-Feremi A
    Neuro Oncol; 2011 Sep; 13(9):1037-46. PubMed ID: 21803763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.